Aarti Pharmalabs Ltd

- No specific mention of any current or planned new fundraising through debt or equity in the transcript. - The company is focusing on brownfield expansions, such as the Xanthine capacity increase and Atali greenfield project, funded through internal resources or existing plans. - CAPEX guidance indicates planned capital expenditure of around INR 550-600 crores over FY25 and FY26, with no explicit discussion on raising fresh capital through equity or debt. - The management appears focused on stabilizing and ramping up capacity before considering additional CAPEX or fundraising. - No direct questions or answers related to new equity or debt issuance were addressed in the sessions on pages 6-16.

- Brownfield expansion at current Xanthine site to increase capacity from 5,000 to 9,000 tonnes; project completion expected by Q3 next fiscal year with full operationalization over subsequent 2-3 quarters. - Expansion includes filing for USFDA DMF and EUGMP CEP regulatory approvals within current fiscal year, targeting pharmaceutical segment. - Atali greenfield project for CDMO/CMO and intermediate manufacturing progressing well; commissioning expected by Q4 FY25; phase one will have 60 reactors (+450 KL capacity) with scope for annual incremental expansions. - Additional brownfield expansions and debottlenecking planned at Tarapur API site to meet growing demand. - Total planned CAPEX of ₹550-600 crores over current and next fiscal years: - ₹170 crores invested in H1 FY25 - ₹250 crores planned in H2 FY25 - ₹150 crores planned in H1 FY26 - No immediate new CAPEX planned for Xanthine beyond current expansion; strategy to stabilize capacity before additional investments.

- Xanthine segment capacity expanding from 5000 to 9000 MT, expected full operationalization by FY27 with phased ramp-up starting H2 FY26. - Future focus shifting toward pharmaceutical Xanthine in regulated markets, targeting 20-25% capacity allocation to pharma segment to stabilize margins. - CDMO/CMO business growth guidance revised lower from 25% to around 20% due to some project delays, but strong growth expected next year and beyond. - API segment volumes expected to grow due to capacity debottlenecking and filling Atali intermediate facility in FY26. - FY26 growth driven mainly by product mix, stable volumes, and CDMO/CMO; FY27 anticipated to deliver bulk of 15% CAGR target with new capacities. - Long-term revenue potential from CDMO projects ranges $25-$50 million per molecule if commercialized successfully. - Overall, cautious growth guidance aiming to achieve at least 15% EBITDA CAGR over next 3 years.

- The company expects EBITDA growth of 10% to 12% in FY25 and a long-term annual growth target of about 15% over the next few years. - FY27 is anticipated to be the key year for significant capacity expansions (Xanthine and Atali site) to come online, driving volume growth and margin improvements. - CDMO/CMO segment growth might be slightly pushed to FY26 from FY25 due to project timing but is expected to show strong growth going forward. - The Xanthine segment is moving from spot to regulated markets, stabilizing margins despite pricing pressures. - Continuous cost optimization efforts (e.g., solar energy, bio gas) are expected to support margin improvement. - Management remains cautious with guidance to avoid over-commitment but confident of surpassing the stated targets in the medium to long term.

- The company is currently working with 19 customers on 55 CDMO/CMO projects. - Out of these, 28 projects are in the commercial stage and 27 are in developmental stages. - CDMO/CMO orders are multi-stage with long lead times; some high-value orders' deliveries are scheduled later this year, possibly extending revenue realization beyond the current financial year. - The company sees increased engagement in CDMO/CMO with more customer visits and RFPs, indicating a strong order pipeline. - For API and intermediate segments, capacity expansions and new product commercialization indicate ongoing order growth. - The Xanthine segment maintains strong long-term contracts despite spot market pressure; capacity ramp-up expected to boost orderbook. - Overall, the outlook is positive with strong medium to long-term order pipeline especially in CDMO/CMO and regulated API markets.